Alcon Stock News

Investors are optimistic about Alcon's (ALC) better-than-expected results and robust segmental performance.

Investors are optimistic about Alcon's (ALC) better-than-expected results and robust segmental performance.

Since my previous article on ALC, the stock is down ~10% vs. ~6% for the S&P 500 and is now fairly valued in my opinion for a 6% return.

If history is any guide, there may be trouble ahead for shares of Alcon (NYSE: ALC ). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock. What To Know: Many traders use moving average crossover systems to make their decisions. When a shorter-term average price crosses above a longer-term average price, it could mean the stock is trending higher. If the short-term average price crosses below the long-term … Full story available on Benzinga.com

With the latest launch, Alcon's (ALC) Clarion Monofocal, Clareon PanOptix, Clareon PanOptix Toric, Clareon Vivity and Clareon Vivity Toric IOLs are now available in the United States.

With the latest launch, Alcon's (ALC) Clarion Monofocal, Clareon PanOptix, Clareon PanOptix Toric, Clareon Vivity and Clareon Vivity Toric IOLs are now available in the United States.

In Surgical, Alcon (ALC) remains the market leader in presbyopia correcting IOLs on the strength of both PanOptix and Vivity.

Alcon (NYSE: ALC ) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:30 PM. Here''s what investors need to know about the announcement. Earnings Alcon beat estimated earnings by 14.29%, reporting an EPS of $0.56 versus an estimate of $0.49. Revenue was up $209.00 million from the same period last year. Past Earnings Performance Last quarter the company … Full story available on Benzinga.com

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ: LXRX ) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (NASDAQ: PRAX ) is likely to report earnings for its fourth quarter. • Blackstone Secured (NYSE: BXSL ) is likely to report quarterly earnings at $0.59 per share on revenue of $171.69 million. • Mersana Therapeutics (NASDAQ: MRSN ) is estimated to report earnings for its fourth quarter. • Partner Communications Co (NASDAQ: PTNR ) is expected to report earnings for its fourth quarter. • Daqo New Energy (NYSE: DQ ) is expected to report quarterly earnings at $4.58 per share on revenue of $698.65 million. • Easterly Government Props (NYSE: DEA ) is likely to report quarterly earnings at $0.10 per share on revenue of $72.20 million. • Aurinia Pharmaceuticals (NASDAQ: AUPH ) is expected to report earnings for its fourth quarter. • Kosmos Energy (NYSE: KOS ) is estimated to report quarterly earnings at $0.15 per share on revenue of $380.

SAN FRANCISCO , Feb. 24, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Contact Lenses - Global Market Trajectory & Analytics" . The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE What''s New for 2022? Global competitiveness and key competitor percentage market shares Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to our digital archives and MarketGlass Research Platform Complimentary updates for one year Edition: 18; Released: February 2022 Executive Pool: 5714 Companies: 94 - Players covered include Alcon, Inc.; Bausch Health Companies, Inc.; CooperVision, Inc.; Ginko International Co., Ltd.; Johnson & Johnson Vision Care, Inc.; Menicon Co., Ltd; St. Shine Optical Co., Ltd. and Others.

Analysts have provided the following ratings for Alcon (NYSE:ALC) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 3 0 0 Last 30D 0 1

Alcon CEO David Endicott says he expects all geographies to return to pre-pandemic growth levels in 2022. He speaks with CNBC's Julianna Tatelbaum following the eyecare company's full-year 2021 earnin

Alcon AG (NYSE: ALC ) reported Q4 FY21 sales of $2.13 billion , +11% Y/Y on a reported basis and +13% on a constant currency (cc) basis, beating the consensus of $2.04 billion. Eye care markets in the fourth quarter reflected the recovery in the U.S. and the continuing recovery internationally from the COVID-19 pandemic. It reported a core EPS of $0.56, surpassing the Wall Street estimate of $0.49, … Full story available on Benzinga.com